Is Samrat Pharmachem a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Samrat Pharmachem Ltd is a average quality company .

Is Samrat Pharmachem undervalued or overvalued?

The key valuation ratios of Samrat Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Samrat Pharmachem share price return in the past 10 years?

Samrat Pharmachem Ltd share price has appreciated 28.3% annually (CAGR) over the past ten years.

Is Samrat Pharmachem a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Samrat Pharmachem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Samrat Pharmachem Ltd - Stock Valuation and Financial Performance

Name: Samrat Pharmachem
Brand: Samrat Pharmachem

BSE: 530125 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Samrat Pharmachem Share Price

₹343.95 2.65 0.78%
as on 23-Jun'25 16:59

10 Year X-Ray of Samrat Pharmachem:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	6.5%	5.3%	16.4%	23.1%	11.8%	22.4%	23.9%	52.3%	34.9%	4.1%	-
Value Creation Index ⓘ	-0.5	-0.6	0.2	0.7	-0.2	0.6	0.7	2.7	1.5	-0.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	48.5	63.2	72.8	92.9	111	137	179	222	311	282	286
Sales YoY Gr.	-	30.4%	15.1%	27.8%	19.6%	23.7%	30.2%	23.9%	40.1%	-9.4%	-
Adj EPS ⓘ	1.1	1	5.7	10.4	5	13.7	17.3	55.5	53.4	4.7	23
YoY Gr.	-	-10.4%	494.7%	84.3%	-52.3%	176.5%	25.9%	220.6%	-3.7%	-91.3%	-
BVPS (₹) ⓘ	43.6	44.5	49.6	60	65	78.7	95.9	151.5	204.4	210.4	232.4
Adj Net Profit ⓘ	0.3	0.3	1.7	3.2	1.5	4.3	5.3	17.1	16.5	1.4	7
Cash Flow from Ops. ⓘ	-0.6	-0.4	-3.2	0.1	2.4	-1.3	4.8	17.5	-9.4	9.4	-
Debt/CF from Ops. ⓘ	-5.9	-15.4	-2.2	71.9	2.8	-7.1	1.8	0.4	-2	0.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	21.6%	20.4%	16.3%	-9.4%
Adj EPS ⓘ	17.9%	-1.3%	-35.5%	-91.3%
BVPSⓘ	19.1%	26.5%	29.9%	2.9%
Share Price	28.3%	35.3%	-4.3%	-0.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	2.5	2.2	12	19	8	19.1	19.8	44.8	30	2.2	10.4
Op. Profit Mgn % ⓘ	2.4	1.9	5.1	6.4	2.9	4.8	4.8	10.9	7.7	0.9	3.6
Net Profit Mgn % ⓘ	0.7	0.5	2.4	3.5	1.4	3.1	3	7.7	5.3	0.5	2.5
Debt to Equity ⓘ	0.2	0.4	0.5	0.5	0.3	0.4	0.3	0.2	0.3	0.1	0
Working Cap Days ⓘ	120	103	116	98	89	93	84	87	89	123	68
Cash Conv. Cycle ⓘ	20	23	33	46	45	40	37	45	48	60	33

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.30%

Return on Equity has declined versus last 3 years average to 10.40%

Net Profit has been subdued in last 3 years -35.46%

Sales growth is not so good in last 4 quarters at 4.49%

Latest Financials - Samrat Pharmachem Ltd.

	Standalone	Consolidated
TTM EPS (₹)	23	-
TTM Sales (₹ Cr.)	286	-
BVPS (₹.) ⓘ	232.4	-
Reserves (₹ Cr.) ⓘ	69	-
P/BV ⓘ	1.48	-
PE ⓘ	14.94	-

From the Market
52 Week Low / High (₹)	302.05 / 646.00
All Time Low / High (₹)	0.95 / 1250.00
Market Cap (₹ Cr.)	106
Equity (₹ Cr.)	3.1
Face Value (₹)	10
Industry PE ⓘ	40.7

Management X-Ray of Samrat Pharmachem:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Samrat Pharmachem

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Samrat Pharmachem

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	48	63	73	93	111	137	179	222	311	282
Operating Expenses ⓘ	47	62	69	87	108	131	170	198	287	279
Manufacturing Costs	1	2	2	2	2	2	3	4	4	4
Material Costs	43	56	63	82	103	126	164	190	278	270
Employee Cost	1	1	1	1	1	1	1	1	1	1
Other Costs ⓘ	2	3	3	2	2	2	2	3	4	4
Operating Profit ⓘ	1	1	4	6	3	7	9	24	24	2
Operating Profit Margin (%)	2.4%	1.9%	5.1%	6.4%	2.9%	4.8%	4.8%	10.9%	7.7%	0.9%
Other Income ⓘ	0	0	0	0	0	1	0	1	0	1
Interest ⓘ	1	1	1	1	1	1	1	1	1	1
Depreciation ⓘ	0	0	0	0	0	0	0	1	1	1
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0	0	3	5	2	6	7	24	23	3
Tax ⓘ	0	0	1	2	1	2	2	6	6	0
Profit After Tax	0	0	2	3	2	4	5	17	17	2
PAT Margin (%)	0.7%	0.5%	2.4%	3.5%	1.4%	3.1%	3.0%	7.7%	5.4%	0.8%
Adjusted EPS (₹)	1.0	1.0	5.7	10.4	5.0	13.7	17.3	55.6	53.8	7.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	2%	2%	14%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	13	14	15	19	20	24	30	47	63	65
Share Capital ⓘ	3	3	3	3	3	3	3	3	3	3
Reserves ⓘ	10	11	12	15	17	21	27	44	60	62
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	3	5	7	9	6	9	9	8	19	8
Long Term Debt	0	2	1	1	0	0	0	0	0	0
Short Term Debt	3	4	5	8	6	9	9	8	19	8
Trade Payables	9	16	7	10	13	23	18	23	32	48
Others Liabilities ⓘ	1	1	7	3	1	2	1	7	3	1
Total Liabilities ⓘ	26	36	36	41	40	58	57	85	117	122
Fixed Assets
Gross Block	9	10	10	11	11	11	14	15	16	17
Accumulated Depreciation	2	3	3	4	4	4	5	5	6	6
Net Fixed Assetsⓘ	7	7	7	7	7	7	9	10	11	11
CWIP ⓘ	0	0	0	0	0	1	0	0	0	0
Investmentsⓘ	0	2	0	0	0	0	0	0	2	3
Inventories	4	6	7	7	8	19	11	12	33	21
Trade Receivables	10	16	12	22	21	28	33	44	52	69
Cash Equivalents	4	3	2	4	2	1	3	15	12	10
Others Assetsⓘ	1	2	8	1	2	2	1	4	8	8
Total Assets ⓘ	26	36	36	41	40	58	57	85	117	122

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-1	0	-3	0	2	-1	5	17	-9	9
PBT ⓘ	0	0	3	5	2	6	7	24	23	3
Adjustment ⓘ	1	1	1	1	1	1	2	1	2	0
Changes in Working Capital ⓘ	-1	-1	-7	-5	0	-8	-2	-6	-24	9
Tax Paid ⓘ	0	0	-1	-1	-2	-1	-2	-2	-9	-2
Cash Flow From Investing Activity ⓘ	0	-2	1	-2	2	-2	-3	-1	-3	0
Capex	0	-1	0	0	0	-1	-3	-1	-1	-1
Net Investments	0	-2	2	-2	2	0	-1	0	-2	0
Others ⓘ	0	0	0	0	0	-1	1	0	0	0
Cash Flow From Financing Activityⓘ	0	2	1	2	-4	2	-2	-2	10	-11
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	1	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	-1	-1	-1	-1	-1	-1	-1	-1
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	1	2	3	-2	3	0	-1	11	-10
Net Cash Flow ⓘ	0	0	-1	-1	1	-1	0	14	-3	-2

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	2.38	2.21	12.07	19.01	7.96	19.1	19.77	44.95	30.25	3.38
ROCE (%)	6.45	5.31	16.4	23.05	11.8	22.43	23.9	52.33	34.91	4.13
Asset Turnover Ratio	1.82	2.19	2.18	2.74	3.09	3.19	3.53	3.12	3.09	2.36
PAT to CFO Conversion(x)	N/A	N/A	-1.5	0	1	-0.25	1	1	-0.53	4.5
Working Capital Days
Receivable Days	72	69	65	58	63	57	54	63	56	78
Inventory Days	42	27	29	24	22	31	27	20	26	34
Payable Days	99	81	68	40	41	52	45	39	36	54

Samrat Pharmachem Ltd Stock News

Samrat Pharmachem Ltd FAQs

What is the share price of Samrat Pharmachem?

Company share prices are keep on changing according to the market conditions. The closing price of Samrat Pharmachem on 23-Jun-2025 16:59 is ₹343.9.

What is the market cap of Samrat Pharmachem?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jun-2025 16:59 the market cap of Samrat Pharmachem stood at ₹106.3.

What is the P/E ratio of Samrat Pharmachem?

The latest P/E ratio of Samrat Pharmachem as of 23-Jun-2025 16:59 is 14.94.

What is the P/B ratio of Samrat Pharmachem?

The latest P/B ratio of Samrat Pharmachem as of 23-Jun-2025 16:59 is 1.48.

What is the 52-week high and low of Samrat Pharmachem?

The 52-week high of Samrat Pharmachem is ₹646.0 and the 52-week low is ₹302.1.

What is the TTM revenue of Samrat Pharmachem?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Samrat Pharmachem is ₹285.9 ( Cr.) .

About Samrat Pharmachem Ltd

Samrat Pharmachem was incorporated on June 16, 1992, at Ankleshwar in Gujarat. It was promoted by Lalit Mehta & Rajesh Mehta. The company is currently manufacturing iodine salts & bromine salts. The finished products produced by the company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc. The products of the company are well received in Indian & foreign markets. The company is a public limited company & its shares are listed & traded on the Bombay Stock Exchange & other bourses of India. The company is presently employing 30 people for its operations at Ankleshwar & Mumbai.

The companyâ€™s manufacturing unit & test laboratory is situated in Ankleshwar. The factory is spread in an area of 3645 sq. mtrs. & has a constructed area of 20000 sq. ft. Technical innovation is their core strength. If anything is possible chemically, they strain their nerves to make it a reality. Research & Development is multi faceted focusing both on product & process development. Their commitment to keep the atmosphere beautiful & pure inspires them for further improvement in the process techniques.

The company is having a modern & well equipped quality control laboratory manned by experienced professionals who have set high standards for testing & approval. Starting with the raw materials, the intermediate stages & right upto the final stage, the products are continuously monitored for quality. The company's products & laboratory is approved by the Food & Drug Administration, Gandhinagar, Gujarat.

Samrat is well equipped to discharge its function round the year without any breakdown under adverse conditions. The company has fully computerized, centrally located office in the heart of Mumbai. Excellent documentation & personal attention to all national & international order ensures smooth & flawless logistical services. The company has well trained staff to meet any contingencies. Safe, convenient & tamper proof packaging ensures easy handling & reliability.The company is heading towards being accredited ISO 9000 & ISO 14000 Certification shortly.

The company is heading towards ERP implementation, which will integrate all the activities of the company on the internet thereby giving speedy information & reports.

Product range of the company includes:

Samrat has a major chunk of the business in Iodine & Bromine Salts. The company's customers include several multinational companies in India & Abroad. The company is exporting a part of its products to USA, Europe, Japan etc.

Calcium Iodate Monohydrate
Copper Iodide
Hydriodic Acid 47%
Hydriodic Acid 57%
Iodine
Iodine Monochloride
Iodoethane (Ethyl iodide)
Iodomethane (Methyl iodide)
Potassium Bromide
Potassium Iodate
Potassium Iodide
Potassium Metaperiodate
Sodium Iodate
Sodium Iodide
Sodium Metaperiodate
Trimethyl Sulfoxoniumiodide

Achievements/ recognition :

The company's products & laboratory is approved by the Food & Drug Administration, Gandhinagar, Gujarat.

SEBI Registered: Investment Adviser - INA000013323 RIA Details

Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.

Compliance Officer:

Name: Shrikant Jagtap

Email: shrikant.jagtap@moneyworks4me.com

Mobile No: +91 97638 00745

Grievance Officer:

Name: Mukta Vaze

Email: mukta.vaze@moneyworks4me.com

Mobile No:+91 98609 19463

Principal Officer:

Name: Atharva Bhide

Email: atharva.bhide@moneyworks4me.com

Mobile No:+91 91758 99463

SEBI regional/local office address-

Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051

Address:

The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Data provided by Accord Fintech Pvt. Ltd.

Please wait your portfolio is updating...

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity - May 16, 2019 - Perpetual
BASL Membership ID:	BASL1187
Address	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Samrat Pharmachem Ltd - Stock Valuation and Financial Performance

Samrat Pharmachem Share Price

DeciZen - make an informed investing decision on Samrat Pharmachem Share

Overall Rating ⓘ M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation ⓘ

3. Price Trend

Samrat Pharmachem stock performance -

Is Samrat Pharmachem Ltd an attractive stock to invest in?

1. Is Samrat Pharmachem Ltd a good quality company?

2. Is Samrat Pharmachem Ltd undervalued or overvalued?

3. Is Samrat Pharmachem Ltd a good buy now?

10 Year X-Ray of Samrat Pharmachem: Share

Analysis of Financial Track Record

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Recent Performance Summary

Latest Financials - Samrat Pharmachem Ltd.

Management X-Ray of Samrat Pharmachem: Share

Shareholding Pattern

Promoter's Holding & Share Pledging